James Hardie Industries (JHX) shares slumped 36% after the company reported late Tuesday a year-over-year decline in fiscal Q1 adjusted earnings and sales.

Truist cuts its price target on the stock to $25 from $35 while keeping its buy rating.

More than 48.2 million shares traded intraday, compared with a daily average of about 6.31 million.

EnVVeno Medical (NVNO) said Wednesday it received a not-approvable letter from the US Food and Drug Administration in response to its premarket approval application for VenoValve, a surgical replacement venous valve to treat deep chronic venous insufficiency.

Shares plunged 71%, with intraday trading volume catapulting to over 12.2 million from a daily average of about 141,000.

Calidi Biotherapeutics (CLDI) said it has priced an underwritten public offering to raise $6 million.

Shares sank 43%, with trading volume of over 2.44 million against a daily average of about 1.48 million.

Price: 1.21, Change: -2.99, Percent Change: -71.24